Literature DB >> 15166110

Measurement of urinary D- and L-2-hydroxyglutarate enantiomers by stable-isotope-dilution liquid chromatography-tandem mass spectrometry after derivatization with diacetyl-L-tartaric anhydride.

Eduard A Struys1, Erwin E W Jansen, Nanda M Verhoeven, Cornelis Jakobs.   

Abstract

BACKGROUND: The differential diagnosis of D-2-hydroxyglutaric aciduria (D-2-HGA), L-2-hydroxyglutaric aciduria (L-2-HGA), and the combined D/L-2-hydroxyglutaric aciduria (D/L-2-HGA) can be accomplished only by the measurement of the corresponding 2-hydroxyglutarate (2-HG). Available methods for the determination of D- and L-2-HG in urine are either time-consuming and expensive or have not been extensively validated. We aimed to develop a method for their rapid and sensitive measurement.
METHODS: We used liquid chromatography-tandem mass spectrometry (LC-MS/MS) for the determination of D- and L-2-HG with stable-isotope-labeled internal standards. Urine samples of 20 microL were mixed with 250 microL of methanol containing the internal standards and subsequently dried under nitrogen. The analytes were derivatized by use of diacetyl-L-tartaric anhydride (DATAN) to obtain diastereomers, which were separated on an achiral C18 HPLC column and detected by MS/MS in multiple-reaction-monitoring mode.
RESULTS: The use of DATAN as chiral derivatization reagent provided very well separated peaks of the formed diastereomers of D- and L-2-HG, with a total runtime of 5 min. The inter- and intraassay CVs for D- and L-2-HG ranged from 3.4% to 6.2%. Mean recoveries of D- and L-2-HG, evaluated on two concentrations, were 94%. Detection limit of the presented method was 20 pmol for a sample volume of 20 microL. Method comparison of the LC-MS/MS method with a gas chromatography-mass spectrometry method, in which D- and L-2-HG were derivatized with R-(-)-butanol, showed good agreement between the two methods.
CONCLUSIONS: Urinary D- and L-2-HG can be analyzed by MS/MS after derivatization with DATAN. The presented method may be suitable for the differential diagnosis of 2-HGA.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15166110     DOI: 10.1373/clinchem.2004.033399

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  58 in total

1.  Combined D2-/L2-hydroxyglutaric aciduria (SLC25A1 deficiency): clinical course and effects of citrate treatment.

Authors:  Chris Mühlhausen; Gajja S Salomons; Zoltan Lukacs; Eduard A Struys; Marjo S van der Knaap; Kurt Ullrich; René Santer
Journal:  J Inherit Metab Dis       Date:  2014-04-01       Impact factor: 4.982

2.  Mutant IDH1 Disrupts the Mouse Subventricular Zone and Alters Brain Tumor Progression.

Authors:  Christopher J Pirozzi; Austin B Carpenter; Matthew S Waitkus; Catherine Y Wang; Huishan Zhu; Landon J Hansen; Lee H Chen; Paula K Greer; Jie Feng; Yu Wang; Cheryl B Bock; Ping Fan; Ivan Spasojevic; Roger E McLendon; Darell D Bigner; Yiping He; Hai Yan
Journal:  Mol Cancer Res       Date:  2017-02-01       Impact factor: 5.852

Review 3.  Metabolomic signature of brain cancer.

Authors:  Renu Pandey; Laura Caflisch; Alessia Lodi; Andrew J Brenner; Stefano Tiziani
Journal:  Mol Carcinog       Date:  2017-07-17       Impact factor: 4.784

4.  Co-morbidity of Sanfilippo syndrome type C and D-2-hydroxyglutaric aciduria.

Authors:  M Ali Pervaiz; Marc C Patterson; Eduard A Struys; Gajja S Salomons; Cornelis Jakobs; Devin Oglesbee; Salman Kirmani
Journal:  J Neurol       Date:  2011-03-08       Impact factor: 4.849

5.  Direct comparison of quantitative digital PCR and 2-hydroxyglutarate enantiomeric ratio for IDH mutant allele frequency assessment in myeloid malignancy.

Authors:  D H Wiseman; E A Struys; D P Wilks; C I Clark; M W Dennis; E E W Jansen; G S Salomons; T C P Somervaille
Journal:  Leukemia       Date:  2015-06-19       Impact factor: 11.528

6.  ADHFE1 is a breast cancer oncogene and induces metabolic reprogramming.

Authors:  Prachi Mishra; Wei Tang; Vasanta Putluri; Tiffany H Dorsey; Feng Jin; Fang Wang; Donewei Zhu; Lauren Amable; Tao Deng; Shaofei Zhang; J Keith Killian; Yonghong Wang; Tsion Z Minas; Harry G Yfantis; Dong H Lee; Arun Sreekumar; Michael Bustin; Wei Liu; Nagireddy Putluri; Stefan Ambs
Journal:  J Clin Invest       Date:  2017-11-27       Impact factor: 14.808

7.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

8.  Selective Detection of the D-enantiomer of 2-Hydroxyglutarate in the CSF of Glioma Patients with Mutated Isocitrate Dehydrogenase.

Authors:  Juliya Kalinina; Jun Ahn; Narra S Devi; Liya Wang; Yuancheng Li; Jeffrey J Olson; Michael Glantz; Thomas Smith; Ella L Kim; Alf Giese; Randy L Jensen; Clark C Chen; Bob S Carter; Hui Mao; Miao He; Erwin G Van Meir
Journal:  Clin Cancer Res       Date:  2016-06-23       Impact factor: 12.531

9.  Hypoxia-Mediated Increases in L-2-hydroxyglutarate Coordinate the Metabolic Response to Reductive Stress.

Authors:  William M Oldham; Clary B Clish; Yi Yang; Joseph Loscalzo
Journal:  Cell Metab       Date:  2015-07-23       Impact factor: 27.287

10.  Saccharomyces cerevisiae Forms D-2-Hydroxyglutarate and Couples Its Degradation to D-Lactate Formation via a Cytosolic Transhydrogenase.

Authors:  Julia Becker-Kettern; Nicole Paczia; Jean-François Conrotte; Daniel P Kay; Cédric Guignard; Paul P Jung; Carole L Linster
Journal:  J Biol Chem       Date:  2016-01-16       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.